8-K filing
8-K: Item 8.01
8-K filing
8-K: Item 8.01
D1 -3.5% · +5d +3.7%
7 earlier events›
RegulationBull
FDA Grants Accelerated Approval for GENGLYCOS Gene Therapy; RARE Shares Rise
First-ever therapy targeting underlying cause of GSDIa; boosts rare-disease portfolio
D1 -3.5% · +5d +3.7%
8-K filing
8-K: Item 8.01
D1 +0.6% · +5d -5.5%
EarningsBull
Ultragenyx Q2 Loss Narrower Than Expected, Revenue Hits Record High
Q2 loss of $0.90/share beat $1.27 estimate; revenue of $214M set quarterly record; shares gapped up pre-market
D1 +3.2% · +5d +4.5%
›2 waves of this story
- 2026-08-04 Q2 EPS loss $0.9 beat estimates, revenue beat, reaffirms FY guidance
- 2026-08-06 Q2 loss of $0.90/share beat $1.27 estimate; revenue of $214M set quarterly record; shares gapped up pre-market
EarningsBull
Ultragenyx Q2 Revenue $214M Beats, Loss Narrows
Q2 EPS loss $0.90 beats $1.27 est; revenue $214M record high; shares gap up premarket
D1 -3.4% · +5d +7.7%
›2 waves of this story
- 2026-08-05 EPS loss $0.90 vs $1.27 est; Crysvita $156M; reaffirms FY guide $730-760M
- 2026-08-06 Q2 EPS loss $0.90 beats $1.27 est; revenue $214M record high; shares gap up premarket
8-K filing
8-K: Item 2.02, Item 9.01
D1 +3.2% · +5d +4.5%
Earnings
Earnings report
D1 +3.2% · +5d +4.5%
8-K filing
8-K: Item 5.02, Item 5.07, Item 9.01
D1 -3.2% · +5d -4.3%
by direction · sourced
Cases AI-clustered from trusted X authors over 2 weeks; counts are distinct authors. Volume does not predict direction · Not investment advice
be the first
Be civil · your views are your own
Facts and opinions separated · All items sourced · Not investment advice
